Q-omics provides the consensus-scored SLC6A14P1 profile across patient tissues and cancer cell-line models. SLC6A14P1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in GBM. Among the 18 cancer types available for tumor–normal comparison, SLC6A14P1 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, SLC6A14P1 RNA expression shows 5,887 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight GBM, BRCA, and STAD as cancer lineages where SLC6A14P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A14P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A14P1 survival associations across molecular data types. SLC6A14P1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A14P1 RNA expression–survival associations across cancer types. High SLC6A14P1 expression shows unfavorable associations in LUSC, KIRC, BLCA and THYM, but favorable associations in GBM and ESCA. The GBM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify GBM as the clearest survival context for SLC6A14P1 RNA expression.
This table summarizes SLC6A14P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC6A14P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A14P1 shows lower tumor expression in BRCA, UCEC and THCA and higher tumor expression in ESCA. The BRCA box plot shows higher SLC6A14P1 RNA expression in normal versus tumor tissue (log2 FC = −0.098, t-test p < 0.001).
This table shows molecular features associated with SLC6A14P1 in patient tissues and cancer cell lines. In patient samples, SLC6A14P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
